• JAK inhibition's cardiovascular, malignancy risks are a ‘moving target'

    2 monthes ago - By Healio

    PHILADELPHIA - Making sense of real-world data and black-box warnings associated with Janus kinase inhibitors can be challenging for rheumatologists hoping to prescribe these medications, according to a presenter at ACR Convergence 2022.
    “It is not my intention to render a verdict today,” Jon Giles, MD, MPH, associate professor of medicine at Columbia University, told attendees.
    Rather, Giles aimed to raise some questions for rheumatologists to consider as they sort through the data and try to optimize the use of JAK inhibition in their patients.
    Currently approved JAK
    Read more ...